血友病B与基因治疗:etranacogene dezaparvovec开启新篇章
本文综述了支持美国食品药品监督管理局(FDA)批准etranacogene dezaparvovec(Hemgenix)的非临床与临床研究。该药是首个获批治疗血友病的基因治疗,也是首个获批的肝靶向腺相关病毒载体基因治疗。2b期(3例)和3期(54例)共57例参与者的短期安全性和表型改善明确,3期96%参与者停用凝血因子IX预防治疗,年化出血率非劣于预防治疗。
要点
- etranacogene dezaparvovec是FDA批准的首个血友病基因治疗及首个肝靶向AAV载体基因治疗。
- 3期试验96%参与者停用FIX预防治疗,年化出血率非劣于FIX预防治疗。
- 年化输注率下降97%,输注后18个月血浆FIX活性较基线最小二乘均值增加34.3个百分点。
核心结论
- FDA对Hemgenix的批准是血友病治疗领域的里程碑,基于超过20年基因治疗临床研究,预示基因组药物的前景。
研究设计与样本
- 综述总结了支持监管 clearance 的非临床研究和临床开发,包括2b期(3例参与者)和3期(54例参与者)研究,共57例参与者。
主要发现
- 最常见不良反应包括肝酶升高、头痛、流感样症状、输注相关反应、肌酸激酶升高、不适和疲劳,多为短暂性。
- 1例参与者在载体输注后1年研究规定的肝脏超声中发现肝细胞癌,切除肿瘤的分子分析显示无载体相关插入突变的证据。
- 3期试验中96%参与者能够停止FIX预防治疗,主要终点年化出血率非劣于FIX预防治疗。
- 关键次要终点年化输注率下降97%,输注后18个月血浆FIX活性较基线最小二乘均值增加34.3个百分点,均具有临床和统计学显著性。
关键数值与推荐
- 3期试验中96%参与者停止FIX预防治疗,年化出血率非劣于FIX预防治疗。
- 年化输注率下降97%。
- 输注后18个月血浆FIX活性较基线最小二乘均值增加34.3个百分点。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The US Food and Drug Administration (FDA)'s authorization of etranacogene dezaparvovec (Hemgenix) is a significant milestone, constituting not only the first FDA approval of a gene therapy for hemophilia but also the first approval of a liver-targeted adeno-associated virus vector gene therapy. This review summarizes the nonclinical studies and clinical development that supported regulatory clearance. Similar to other gene therapies for single gene disorders, both the short-term safety and the phenotypic improvement were unequivocal, justifying the modest-sized safety and efficacy database, which included 57 participants across the phase 2b (3 participants) and phase 3 (54 participants) studies. The most common adverse reactions included liver enzyme elevation, headache, flu-like symptoms, infusion-related reactions, creatine kinase elevation, malaise, and fatigue; these were mostly transient. One participant had hepatocellular carcinoma on a study-mandated liver ultrasound conducted 1 year after vector infusion; molecular analysis of the resected tumor showed no evidence of vector-related insertional mutagenesis as the etiology. A remarkable 96% of participants in the phase 3 trial were able to stop factor IX (FIX) prophylaxis, with the study demonstrating noninferiority to FIX prophylaxis in terms of the primary end point, annualized bleeding rate. Key secondary end points such as the annualized infusion rate, which declined by 97%, and the plasma FIX activity level at 18 months after infusion, with least squares mean increase of 34.3 percentage points compared with baseline, were both clinically and statistically significant. The FDA's landmark approval of Hemgenix as a pioneering treatment for hemophilia stands on the shoulders of >20 years of gene therapy clinical research and heralds a promising future for genomic medicines.
引用
- Anguela XM, High KA. Hemophilia B and gene therapy: a new chapter with etranacogene dezaparvovec. Blood Adv. 2024. PMID: 38592711. doi:10.1182/bloodadvances.2023010511
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。